The Food and Drug Administration has approved Praluent, the first in an experimental class of biotechnology drugs,
which is shown to lower bad cholesterol more significantly than older medicines that have been prescribed for decades. The drug is expected to generate billions in sales for Sanofi and Regeneron Pharamaceuticals. Praluent is considered the first major advancement in heart-disease medication since the introduction of statin drugs more than 20 years ago. Still, some experts question the longterm benefits of the medication. Its price tag is also likely to become an issue, as more scrutiny is placed on the growing costs of drug therapies.